207 related articles for article (PubMed ID: 28255362)
1. HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors.
Martinho O; Silva-Oliveira R; Cury FP; Barbosa AM; Granja S; Evangelista AF; Marques F; Miranda-Gonçalves V; Cardoso-Carneiro D; de Paula FE; Zanon M; Scapulatempo-Neto C; Moreira MA; Baltazar F; Longatto-Filho A; Reis RM
Theranostics; 2017; 7(3):717-732. PubMed ID: 28255362
[TBL] [Abstract][Full Text] [Related]
2. A pan-HER-targeted approach for recurrent or late-stage cervical cancer therapy: mechanisms, recent advances, and clinical prospects.
Liu Y; An Q; Zhao X
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4123-4131. PubMed ID: 32373948
[TBL] [Abstract][Full Text] [Related]
3. [Mechanism of action and preclinical development of afatinib].
Diz Taín P; González AL; García-Palomo A
Med Clin (Barc); 2016 Apr; 146 Suppl 1():7-11. PubMed ID: 27426242
[TBL] [Abstract][Full Text] [Related]
4. Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors.
Urtasun N; Vidal-Pla A; Pérez-Torras S; Mazo A
BMC Cancer; 2015 Apr; 15():223. PubMed ID: 25886138
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
López-Brea M
Med Clin (Barc); 2016 Apr; 146 Suppl 1():1. PubMed ID: 27426240
[No Abstract] [Full Text] [Related]
6. [Evidence on afatinib in patients progressing on a first-line treatment].
Artal Cortés Á; Gimeno Pelegrín J; Alejandro MÁ
Med Clin (Barc); 2016 Apr; 146 Suppl 1():19-24. PubMed ID: 27426244
[TBL] [Abstract][Full Text] [Related]
7. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
[TBL] [Abstract][Full Text] [Related]
8. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
[TBL] [Abstract][Full Text] [Related]
10. Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.
Rani S; Corcoran C; Shiels L; Germano S; Breslin S; Madden S; McDermott MS; Browne BC; O'Donovan N; Crown J; Gogarty M; Byrne AT; O'Driscoll L
Cancer Res; 2014 Jul; 74(14):3821-33. PubMed ID: 24876102
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor as a biomarker for cervical cancer.
Soonthornthum T; Arias-Pulido H; Joste N; Lomo L; Muller C; Rutledge T; Verschraegen C
Ann Oncol; 2011 Oct; 22(10):2166-78. PubMed ID: 21325449
[TBL] [Abstract][Full Text] [Related]
12. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Zhang X; Munster PN
Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
[TBL] [Abstract][Full Text] [Related]
13. Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.
De Silva N; Schulz L; Paterson A; Qain W; Secrier M; Godfrey E; Cheow H; O'Donovan M; Lao-Sirieix P; Jobanputra M; Hochhauser D; Fitzgerald R; Ford H
Br J Cancer; 2015 Nov; 113(9):1305-12. PubMed ID: 26484410
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer.
De Pauw I; Wouters A; Van den Bossche J; Peeters M; Pauwels P; Deschoolmeester V; Vermorken JB; Lardon F
Pharmacol Ther; 2016 Oct; 166():71-83. PubMed ID: 27373506
[TBL] [Abstract][Full Text] [Related]
15. [Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].
Taus Á
Med Clin (Barc); 2016 Apr; 146 Suppl 1():30-5. PubMed ID: 27426246
[TBL] [Abstract][Full Text] [Related]
16. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
Sachdev JC; Jahanzeb M
Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
[TBL] [Abstract][Full Text] [Related]
17. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
Breast Cancer Res Treat; 2015 Oct; 153(3):493-505. PubMed ID: 26400847
[TBL] [Abstract][Full Text] [Related]
18. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
Goncalves A; Fabbro M; Lhommé C; Gladieff L; Extra JM; Floquet A; Chaigneau L; Carrasco AT; Viens P
Gynecol Oncol; 2008 Jan; 108(1):42-6. PubMed ID: 17980406
[TBL] [Abstract][Full Text] [Related]
20. [Tumor resistance to HER2 inhibitors: the drug sedimentation concept].
Campone M; Frenel JS; André F; Bachelot T; Juin P
Bull Cancer; 2012 Jun; 99(6):665-72. PubMed ID: 22614782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
